

# CLINICAL PHARMACOLOGY & THERAPEUTICS

## INFORMATION FOR AUTHORS

Send manuscripts and all other editorial communications to:

C. Michael Stein, MD, Editor  
*Clinical Pharmacology & Therapeutics*  
Division of Clinical Pharmacology  
560 RRB  
Vanderbilt University School of Medicine  
Nashville, TN 37232-6602

Telephone: (615) 936-3420  
E-mail: [michael.stein@vanderbilt.edu](mailto:michael.stein@vanderbilt.edu)

## CONTENT OF THE JOURNAL

*Clinical Pharmacology & Therapeutics* is a monthly journal devoted to the publication of articles of high quality concerned with effects of drugs **in human beings** and invites original articles in this field. Hypothesis-driven studies (as opposed to observational studies) are especially encouraged. Several broad categories are of interest to our readers:

### *Commentaries:*

Brief, thoughtful essays on topics relevant to clinical pharmacology (particularly public policy, drug regulation or development, and education) may be submitted.

### *Perspectives in Clinical Pharmacology:*

Articles provide state-of-the-art education about a topic of general interest **from a clinical pharmacology perspective**. These articles are solicited by the Editor; potential contributors should approach the Editor before submitting work. Standard review articles about drugs, classes of drugs, or treatment of a disease are normally not accepted.

## ORIGINAL ARTICLES

### *Pharmacokinetics and Drug Disposition:*

Papers should have wide generalizability or represent advances in technical or conceptual methodology and understanding of drug disposition. Articles that only describe the kinetics or bioavailability of a drug in normal subjects or the population pharmacokinetics of a drug whose pharmacokinetics are otherwise well known are not usually published.

### *Pharmacodynamics and Drug Action:*

These papers describe the actions of drugs in humans and study the mechanism of action of drugs.

### *Clinical Trials and Therapeutics:*

Papers include controlled clinical trials and studies that examine therapeutic effects of drugs.

### *Pharmacogenetics and Pharmacogenomics:*

Studies of genetic factors influencing drug disposition, drug action, and adverse drug reactions are of interest, particularly genotype-phenotype associations.

### *Pharmacoepidemiology and Drug Utilization Studies:*

Studies of drugs that are widely used or are of particular public health importance, or that seek to improve prescribing are encouraged.

### *Clinical Pharmacology Grand Rounds:*

These articles include reports of cases in which observations are made that can be used to illustrate a principle of clinical pharmacology that is applied in therapy. The discussion must be limited and focused on the specific teaching point of the case. Case reports without a clinical pharmacology teaching point are not considered.

### *Letters to the Editor:*

Letters to the Editor of fewer than 400 words, including references, that comment on articles previously published in the Journal will be considered.

### *Book Reviews:*

Occasional reviews of books of particular interest to clinical pharmacologists are published. Books reviewed may be textbooks, biography, history, or fiction and are solicited and published at the discretion of the Editor.

*Clinical Pharmacology & Therapeutics* welcomes papers that do not fit into a specific category but do contribute to the knowledge base of the effects of drugs in human beings. In vitro studies of human-derived materials that could not be done with materials derived from other species and papers that include animal experimental data in addition to human data are also of interest, provided that the primary focus of the paper is on drugs in human beings.

## SUPPLEMENTS

Supplements to the Journal are occasionally published. These are usually proceedings of meetings or guidelines produced by an authoritative body on topics that are of interest to clinical pharmacologists. Supplements that deal with a single drug or the products of a single company or that serve marketing or advertising functions are not published. All contents of supplements are peer reviewed and may be rejected by the Editor. The cost of publishing a supplement is borne by its organizers.

**Copyright.** Articles are accepted on the condition that they are contributed solely to *Clinical Pharmacology & Therapeutics*. It is assumed that all of the observations reported in a manuscript are original, have not been previously published, and are not under consideration by another journal, and it is the corresponding author's responsibility to indicate any data previously published in any form or in press. A paper from a study that has generated multiple publications should include references to all papers that have presented any data that are included in the report and copies of papers should be included and mentioned in the cover

letter. Papers that present data that may be included in a future report should mention such a possibility in a footnote and the information must be included in the cover letter. Commentaries and addresses submitted for publication may contain, in part, material that has been previously published but appropriate permission must be obtained by the author. All material published in this Journal is copyrighted and may be reproduced only with the permission of the publisher. Statements and opinions expressed in articles and communications herein are those of the author(s) and not necessarily those of the Editor, publisher, or American Society for Clinical Pharmacology and Therapeutics, and the Editor, publisher, and American Society for Clinical Pharmacology and Therapeutics disclaim any responsibility or liability for such material. Neither the Editor nor the publisher nor the American Society for Clinical Pharmacology and Therapeutics guarantees, warrants, or endorses any product or service advertised in this publication, nor do they guarantee any claim made by the manufacturer of such product or service.

#### COPYRIGHT TRANSFER

**In accordance with the Copyright Act of 1976, which became effective on January 1, 1978, copyright ownership** is to be transferred to the American Society for Clinical Pharmacology and Therapeutics. A copyright transfer form that must be signed by all authors will be sent to the corresponding author if a manuscript is accepted or if a revised manuscript is requested. The enclosure of a copyright transfer form in a request for a revised manuscript does not imply that the revised manuscript will be accepted.

#### CONFLICT OF INTEREST AND ETHICS

**Conflict of interest and sources of funding.** A potential conflict of interest exists when an author or the author's institution has financial or personal relationships that could influence or could be perceived to influence the work. A conflict can be actual or potential, and therefore full disclosure is best (see "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" available at <http://www.icmje.org/>). All submissions must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest, and these will be published with the manuscript.

The Editor and Associate Editors will recuse themselves from involvement in processing manuscripts where they identify a conflict of interest. A reviewer should not review a manuscript if there is a conflict of interest.

**Ethical obligations.** The Journal follows the guidelines describing the ethical obligations of authors, reviewers, and editorial staff in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (available at <http://www.icmje.org/>). It is the authors' responsibility to inform the Editor if there is more than one manuscript published, in process or planned, that will share data and to enclose copies of those potentially competing manuscripts when a manuscript is submitted. All persons designated as authors should qualify for authorship, and all those who qualify should be listed. Each author must have participated sufficiently to take public responsibility for appropriate portions of the content. Authorship requires that all of the following conditions be met: (1) substantial contributions to concept and design, or acquisition of data, or analysis and interpretation of data; (2)

drafts of the article or critical revisions for important intellectual content; and (3) final approval of the version to be published.

#### MANUSCRIPT SUBMISSION

##### General Instructions

*Clinical Pharmacology & Therapeutics* complies with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (Ann Intern Med 1997;126:36-47; <http://www.icmje.org/>).

- Manuscripts must be typed double-spaced with a 12-point font, including references, figure legends, and tables, on 8 × 11 inch paper on one side of the page with liberal margins.

- Number each page except the title page, including figure legends, tables, and references. Cite each figure and table in text in numeric order.

- Assemble manuscripts in this order: (1) title page; (2) abstract; (3) text, including Introduction, Methods, Results, and Discussion; (4) acknowledgments and conflict of interest statement; (5) references; (6) figure legends; (7) tables; and (8) figures. Staple only the copies of the manuscripts, not the original. Cite each reference in text in numeric order.

- Refer to drugs by accepted generic (public) or chemical names only. Do not abbreviate these names; spell them in full each time they are used. Code numbers alone are not acceptable. USAN is the preferred name; if the USAN and INN differ, the INN should be given in parentheses the first time the drug name is mentioned in the abstract and the first time it is mentioned in the text. Proprietary names should be given in parentheses only at first text mention. Insert IUPAC (International Union of Pure and Applied Chemistry) name if necessary. Specific stereoisomers, if used, or a racemic mixture should be identified as such.

**Hard-copy submission.** 1. Enclose a cover letter that includes the following statement of submission: "All authors have read the manuscript and conflict of interest statement and approved their submission for publication; the work is original and has not been published and is not being considered for publication elsewhere, in whole or in part, in any language, except as an abstract."

Indicate if you have potentially overlapping work that is in preparation, has been previously submitted or published, or is in press.

The cover letter can include the names and addresses of 4 potential reviewers, with e-mail addresses or telephone or fax numbers, who are expert in the area of research and who do not have a conflict of interest. Names of individuals whom the authors believe have a conflict of interest and should not be asked to review the work may also be listed. The Editor may or may not decide to solicit reviews from the persons listed.

2. Send 4 copies of the full manuscript, including one original copy, and one full set of original figures on glossy-finish paper. Manuscripts will not be returned. A stamped, self-addressed large envelope should be sent if authors want the figures from a rejected manuscript to be returned.

3. If applicable, enclose a copy of any potentially overlapping work that is in preparation, has been previously submitted or published, or is in press.

**Electronic submission.** A cover letter and manuscript in Word or WordPerfect can be e-mailed to the Editor at:

michael.stein@vanderbilt.edu. All electronic figures must be accompanied by a high-quality hard copy on glossy paper. When the article is accepted, electronic figures will have to meet the publisher's requirements (see Author Gateway at <http://authors.elsevier.com>).

**Revised manuscripts.** Revised manuscripts should follow the General Instructions, but the title page should include the manuscript number and R1 (for first revision). One copy of the revised manuscript should be marked with word-processing tools such as "track changes," "highlight," or "underline" to indicate precisely the changes that have been made. Enclose a diskette in IBM PC-compatible format containing the final version (Word or WordPerfect preferred). Label and date the diskette. The author accepts responsibility for the submitted diskette exactly matching the printout of the final version of the manuscript. Revisions not received within 3 months will be administratively withdrawn. At the Editor's discretion, extensions may be granted for revisions. A copyright transfer agreement will be enclosed in the request for revision. It must be signed by all authors and accompany the revised manuscript.

### Specific Instructions

1. Title page: Make the title specific and short (there is a limit of 80 characters). Include the first name and the highest earned academic degree for each author. Include the name and address of the institution from which the work originated and sources of all financial support for the work. List the name, e-mail address, complete mailing address, and telephone and fax numbers of the corresponding author. List the number of pages, number of figures, and number of tables and suggest a short title for your paper and the Journal category under which it should appear.

2. Abstract: Supply an abstract of no more than 150 words, which will appear underneath the title. A structured abstract (see *Ann Intern Med* 1990;113:69-76 for details) of up to 250 words may be used instead of the regular 150-word abstract. Do not use acronyms or abbreviations or cite references. The abstract should include the rationale for the study, a brief description of methods and presentation of significant results, and a succinct interpretation of the data.

3. Text (Introduction, Methods, Results, and Discussion): Use only standard abbreviations for measurements and omit periods; explain in tabular form all other abbreviations and acronyms. Limit these other abbreviations and acronyms to those in common use; do not invent abbreviations but rather spell out the terms fully each time they are used.

The Journal endorses the principles embodied in the Declaration of Helsinki and assumes that authors of papers submitted to the Journal will have followed all ethical and legal standards for performing experiments on human beings or animals as set forth by their institutions and states. Manuscripts that describe studies on humans must indicate in the Methods that the study was approved by an institutional review committee and that the subjects gave informed consent.

4. Acknowledgments and conflict of interest statement: This should be placed at the end of the text and before the reference list. The acknowledgments should include only the names of those who have made a scientific contribution.

**All authors** must disclose any financial and personal relationships that could potentially be perceived as influencing their described research or state that there are none. Examples of financial conflicts include employment, consul-

tancies, stock ownership, honoraria, paid expert testimony, patent applications, and research and travel grants within 3 years of beginning the work submitted. If there are no conflicts of interest, authors should state that there are none. For example: "Dr A has stock in company Y and has received research funding from company X; Dr B is an employee of company Y and holds stock options; Dr C has no conflict of interest, and Dr D has received honoraria from companies X, Y and Z and consulted for X." Conflict of interest statements will be published at the end of the paper.

If individuals other than the authors contributed significantly to the writing or editing of the manuscript, their names, roles, and conflict of interest statements should be provided, together with a signed statement from each individual indicating that this information can be published.

5. References: Place the reference list immediately after the acknowledgments. Type the list double-spaced according to the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (*Ann Intern Med* 1997;126:36-47). Journal names are to be abbreviated as they are in the *Cumulated Index Medicus*. "In press" references may be used only if the journal that has accepted the manuscript is indicated. Personal communications and other unpublished and nonarchival references should not be included in the reference list. Instead, make these footnotes to the text; state the source, and date the item.

**Examples of references** (if there are 6 or fewer authors, list all of them; if there are 7 or more, list the first 6 authors and add et al):

#### *Periodicals:*

You CH, Lee KY, Chey RY, Menguy R. Electrogastrographic study of patients with unexplained nausea, bloating and vomiting. *Gastroenterology* 1980;79:311-4.

#### *Books:*

Eisen HN. Immunology: an introduction to molecular and cellular principles of the immune response. 5th ed. New York: Harper & Row; 1974. p. 406.

#### *Chapters in books:*

Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman WA Jr, Sodeman WA, editors. Pathologic physiology: mechanism of disease. Philadelphia: WB Saunders; 1974. p. 457-72.

6. Appendixes: Extensive or very detailed descriptions of analytic methods of mathematic calculations should be included as appendixes, following the references. A short legend may be necessary.

7. Figure legends, tables and figures: Type figure legends double-spaced on a separate page marked "Legends for figures." If a figure has been previously published, the legend must give full credit to the original source and the author must obtain permission for reproduction.

Number tables in Roman numerals in order of mention in the text; all tables must be mentioned. Type tables double-spaced, including title, column heads, body, and footnotes. The title must concisely describe the content of the table, and column heads must do the same for the data in the columns. If a table or any data therein have been previously published, a footnote to the table must give full credit to the original source and the author must obtain permission for reproduction.

Each copy of the manuscript should include a photocopy of each of the figures. Illustrations will be scanned electronically. Unless printed by a high-resolution printer (1200 dpi or better), laser-printed illustrations should be furnished in a larger size, preferably 6 inches or more wide. Photocopies are not acceptable as original illustrations. Preferred fonts for value labels and legends are Arial, Courier, Helvetica, Symbol, or Times Roman. Bold or italic typefaces are not acceptable unless used to emphasize particular words or phrases. The ordinate should be labeled vertically. Labels directly on the graph rather than in the legend are encouraged. Type size must be 14 point or more and line width 1 point or more for 6-inch graphics. The fill for bar graphs or pie charts should be distinctive: avoid shading because different shades of gray (including black) tend to become indistinguishable. If more than 2 bars are used in a graph, please use cross-hatching for adequate contrast. Fills with unnecessary patterns will be returned for revision. Three-dimensional graphics may be used only when there are 3 coordinates (x, y, and z). Black and white graphs or drawings must be legible and clearly printed in jet-black ink on heavy paper; typewritten or freehand lettering is unacceptable. Any special instructions regarding sizing or grouping should be noted clearly. All lettering must be done professionally and should be sized in proportion to the drawing, graph, or photograph. Make sure that decimal points, dotted lines, and the like are dark enough to reproduce plainly. Do not send original artwork, x-ray films, or electrocardiogram (ECG) strips.

In addition, submit ONE ORIGINAL of each photograph or laser- or plotter-printed figure. If computer-generated originals of figures are not available, one set of professionally prepared glossy or matte finish prints must be submitted. The photocopies are sent to the reviewers, and the set of original illustrations is used for reproduction in the Journal. Figures must be cited in the text and must be numbered in order of mention. The first author's last name, the figure number, and an arrow to indicate the top edge should be marked lightly on the back of each figure. A reasonable number of black and white illustrations will be reproduced free of charge to the author, but special arrangements must be made for extra illustrations, color plates, or elaborate tables. Illustrations will not be returned.

8. Permissions: Direct quotations, tables, or illustrations that have appeared in copyrighted material must be accompanied by written permission for their use from the copyright owner and original author along with complete information as to source. Photographs of identifiable persons must be accompanied by signed releases that show informed consent.

9. Page charges: An article charge of \$35 per page for the first 8 printed pages is made. For pages numbered 9 through 16 the charge per page is \$50, and for additional pages the charge per page is \$100. Authors who do not have funds available may request approval for waivers from the Editor. Editorial consideration is in no way related to acceptance of page charges. Waivers should not be sought until after the author receives a bill.

#### REVIEW PROCESS

An acknowledgment that your manuscript has been received will be sent to the corresponding author by e-mail. New manuscripts are reviewed by the Editor and an Associate Editor and if in their opinion the work is not suitable

for the Journal or is unlikely to have high enough priority for publication, it will be rejected without review and the corresponding author will be notified. Manuscripts that undergo full review are sent to at least 2 reviewers and are usually processed within 8 weeks. The manuscript will be rejected or the authors will have the opportunity to submit a revision. A revised manuscript must be received within 3 months or it will be administratively withdrawn. Manuscripts and illustrations will not be returned.

#### ANNOUNCEMENT

The Journal will publish official notices of affiliated societies only.

#### BOOKS RECEIVED

Receipt of books and monographs, domestic and international, will be acknowledged.

#### REPRINTS

Author reprints of articles can be ordered directly from Periodical Reprints, Elsevier, 11830 Westline Ind Dr, St Louis, MO 63146-3318. Telephone 800-325-4177, ext 4350, or 314-453-4350; fax 314-579-3358; e-mail *author.reprints@elsevier.com*, who will send a schedule of prices. To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc, 360 Park Ave South, New York, NY 10010-1710. Fax 212-462-1955; e-mail *reprints@elsevier.com*.

#### CHECKLIST FOR AUTHORS

- Cover letter
- Original and 3 photocopies of typed manuscript, with photocopies of illustrations attached to each
- Title page (double-spaced)
  - Title of manuscript
  - Full name(s), highest earned academic degrees, and affiliations of author(s); institution(s) and city(ies) from which work originated
  - Name, address, and business and home telephone and fax numbers of corresponding author
  - Sources of all financial support
  - Number of pages, number of figures, and number of tables; brief title
- Abstract, 150 words or less (double-spaced)
- Article proper (double-spaced)
- Acknowledgment and conflict of interest statement for each author (double-spaced)
- References (double-spaced), on a separate sheet
- Figure legends (double-spaced), on a separate sheet
- Tables (double-spaced), on separate sheets
- Figures/Illustrations, properly labeled (one original set and attach one set of photocopies to each of the 4 copies of manuscript)
- Permissions to reproduce published material (if applicable)
- Informed consent for patient photographs (if applicable)
- With revision
  - Diskette with revised manuscript
  - Marked copy indicating changes with revised manuscript
  - Copyright transfer agreement signed by all authors with revised manuscript